In their in vivo experiments with melanoma tumors established on the side of mice, they showed that when virus treatment was combined with the delivery of anti-PD-1 antibodies, the number of CD8+ T cells in the tumor significantly increased (compared to the virus alone). Here, CD8A is linked to neoplasm.